The Centers for Medicare & Medicaid Services yesterday released the home health prospective payment system proposed rule for calendar year 2019, which also proposes a major redesign for CY 2020. In CY 2019, the rule would increase net HH payments by 2.1% ($400 million) relative to CY 2018. This includes a 2.7% update to current rates, a productivity adjustment of negative 0.7%, a 0.1% increase related to outlier payments, and a 0.1% decrease due to the new rural payment add-on policy mandated by the Bipartisan Budget Act of 2018. In CY 2020, CMS proposes to implement a new case-mix methodology called the patient-driven groupings model, which would eliminate therapy thresholds in determining payment and change the unit of payment to 30-day periods of care. This budget-neutral implementation of the PDGM was also mandated by the BiBA, and follows a prior iteration put forward by CMS last year, which received extensive feedback from the field. “We are concerned that CMS’s proposed reforms to the HH PPS in CY 2020 appear to be similar to the agency’s prior, flawed iteration of a revised PPS, and will closely evaluate the extent to which they include our recommended changes,” said AHA Executive Vice President Tom Nickels. For CY 2019, the rule also proposes to streamline the HH Quality Reporting Program and the HH Value-Based Purchasing Model; to no longer require the certifying physician to estimate how much longer skilled services are needed when recertifying continued services; and to implement transitional payments for home infusion therapy services; as well as other changes. CMS will accept comments on the proposed rule through Aug. 31.

Related News Articles

Headline
The AHA expressed support Nov. 3 for the bipartisan Home Health Stabilization Act (H.R. 5142), legislation that would establish a two-year pause on planned…
Headline
The AHA and a coalition of organizations yesterday urged House and Senate leaders to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…